Glycyl-Glutamine, an Endogenous β-Endorphin-Derived Peptide, Inhibits Morphine-Induced Conditioned Place Preference, Tolerance, Dependence, and Withdrawal

  1. Sinan Cavun,
  2. Gökhan Göktalay and
  3. William R. Millington
  1. Department of Basic and Pharmaceutical Sciences, Albany College of Pharmacy, Union University, Albany, New York (S.C., G.G., W.R.M.); Ion Technologies, Inc., Winston-Salem, North Carolina (G.G.); and Department of Pharmacology and Clinical Pharmacology, Uludag University School of Medicine, Bursa, Turkey (S.C., G.G.)
  1. Address correspondence to:
    Dr. William R. Millington, Department of Basic and Pharmaceutical Sciences, Albany College of Pharmacy, Union University, 106 New Scotland Ave., Albany, NY 12208. E-mail: millingw{at}acp.edu

Abstract

Glycyl-glutamine (Gly-Gln; β-endorphin30-31) is an endogenous dipeptide synthesized from β-endorphin1-31. Previous investigations have shown that Gly-Gln inhibits the cardiovascular and respiratory depression caused by morphine and β-endorphin1-31, but it does not interfere with opioid analgesia. In this study, we tested whether Gly-Gln administration would influence morphine-induced conditioned place preference, tolerance, dependence, or withdrawal. For place preference experiments, rats were conditioned with morphine sulfate (2.5 mg/kg i.p.) or saline on alternate days for 6 days and tested on day 7. Glycyl-glutamine (1-100 nmol i.c.v.) pretreatment inhibited acquisition of a conditioned place preference to morphine significantly. Glycyl-glutamine (100 nmol i.c.v.) also blocked expression of a pre-established morphine place preference, but it did not interfere with acquisition of a conditioned place preference to palatable food, and it did not produce place preference or aversion when given alone to morphine-naive animals. To induce antinociceptive tolerance, rats were treated with morphine (10 mg/kg i.p.) twice daily for 7 days, and morphine antinociception was evaluated with the tail-flick test. Glycyl-glutamine (100 nmol i.c.v.) pretreatment delayed the onset of morphine tolerance significantly and partially reversed pre-established tolerance. Morphine dependence and withdrawal were assessed by measuring naloxone-precipitated withdrawal symptoms. Glycyl-glutamine inhibited the development of morphine dependence when given to rats twice daily immediately before they received morphine (10 mg/kg i.p.) and suppressed withdrawal symptoms of rats with subcutaneously implanted morphine pellets when administered 5 min before withdrawal was induced with naloxone. Glycyl-glutamine thus attenuates morphine-induced conditioned place preference, tolerance, dependence, and withdrawal without compromising morphine analgesia.

Footnotes

  • This study was supported by Grant DA018029 from the National Institute on Drug Abuse.

  • Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

  • doi:10.1124/jpet.105.091553.

  • ABBREVIATIONS: POMC, proopiomelanocortin; Gly-Gln, glycyl-glutamine; Gly-d-Gln, glycyl-d-glutamine; %MPE, maximal possible effect; ANOVA, analysis of variance; NMDA, N-methyl-d-aspartate.

    • Received June 23, 2005.
    • Accepted July 28, 2005.
« Previous | Next Article »Table of Contents